Sotorasib has been granted approval by the US Food and Drug Administration (FDA) for the treatment of certain patients with KRAS-mutated non-small cell lung cancer (NSCLC); and adagrasib has been given a breakthrough therapy designation by the FDA also for NSCLC (8). This evidence concerns the gene KRAS and non-small cell lung carcinoma.